Loading...

NMRA NEUMORA THERAPEUTICS INC Expansion Plans 8-K Filing

NMR

NMR

NEUMORA THERAPEUTICS INC

(NMRA)

2026 8-K

Financial Results Announcement

Investor Presentation

Investor Presentation

Positive Study Results

Stock Conversion Notice

Financial Results Update

Phase 1 Study Initiated

Positive Drug Data

Financial Statements

Delisting due to Non-Compli...

Financial Statements

Financial Results

Leadership Changes

Leadership Changes

Investor Presentation

Q3 Financial Results

External Links:

On January 5, 2026, Neumora Therapeutics reported positive results from its Phase 1b study of NMRA-511 for Alzheimer’s agitation and shared key pipeline updates and anticipated milestones for 2026.

AI Assistant

NEUMORA THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.